Quarterly report · Q2
4572.TEDINET S100OSD0
Period2022-01-01 → 2022-06-30
Filed2022-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥840m | 2022-01-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥2.0bn | 2021-01-01 → 2021-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥430m | 2021-01-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | −¥312m | 2022-01-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | −¥777m | 2021-01-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | −¥306m | 2022-01-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥523m | 2021-01-01 → 2021-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥775m | 2021-01-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥349m | 2022-01-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥781m | 2021-01-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥359m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥534m | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥776m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥359m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | −¥776m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥5.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥5.4bn | at 2021-12-31 | Cons. | Assets |
| Total assets | ¥3.7bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥792m | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥1.1bn | at 2021-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.4bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥4.3bn | at 2021-12-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.8bn | at 2021-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.7bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.8bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.2bn | at 2021-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥585m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.5bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥963m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥57m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥42m | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥34m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥166m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥102m | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-26.53 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-25.25 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-42.1 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-62.56 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-39.46 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 84.7% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.3% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 10
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥286m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥286m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | −¥547m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥553m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥553m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥235m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | −¥922m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥430m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥430m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥145m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 439
| Item | Context | Value | Unit |
|---|---|---|---|
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)村山 俊彦 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)マネックス証券株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)東京都港区赤坂1丁目12-32 | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)堀田 和男 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)愛知県岡崎市 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)自己保有株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準的となる株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding allowances directly deducted from balances of assets (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |